The SmartCube® platform offers an unbiased way to industrialize phenotypic drug discovery for CNS disorders by screening compound libraries in a manner that is agnostic to mechanism, thus often resulting in novel pharmacology.
We use cookies to personalise content and to analyse our traffic.
You consent to our cookies if you continue to use our website. Read more details in our
cookies policy.